Dr. Daniel Sanford
Dr. Daniel Sanford is an expert in working with deadly diseases. Over his career, he’s led safety and efficacy studies for medical countermeasures against anthrax, melioidosis, botulism, bubonic plague and many other pathogens and biological warfare agents. A Senior Research Scientist and Study Director at the Battelle Biomedical Research Center (BBRC), Dan conducts safety and efficacy studies required to bring new therapies and vaccines to market. His background includes extensive experience in bacterial pathogenesis, medical countermeasure discovery, infectious disease/containment lab research and animal model development. Much of his work is conducted under the FDA Animal Rule; Dan was involved in the licensure of the very first product (Raxibacumab) for which the effectiveness was based solely on efficacy studies in animals. Since then, Dan has directed model development and efficacy studies designed to test vaccines and therapies againstBacillus anthracis, Botulinum Neurotoxin, Ricin, Burkholderia pseudomallei, Burkholderia mallei, and Yersinia pestis.